In particular, LRRK2-IN-1 (XMD11-50), another creation of the Gray lab, developed to target the key Parkinson’s disease target LRRK2, has been used to study potential effects of DCLK1 kinase inhibition in colorectal cancer, pancreatic cancer, head and neck cancer, and cholangiocarcinoma [16,27,28,29,30]. Here, LRRK2 is linked to colorectal cancer.